Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Blood advances·2026
Same author

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.

Blood·2026
Same author

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Beyond age: Frailty-guided care in hematologic malignancies.

Cancer·2026

Related Experiment Video

Updated: Oct 6, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Engineered T Cells: CAR T Cell Therapy and Beyond.

P Connor Johnson1, Jeremy S Abramson2

  • 1Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA.

Current Oncology Reports
|January 21, 2022
PubMed
Summary

Engineered T cell therapies, including approved chimeric antigen receptor (CAR) T cells, are transforming treatment for non-Hodgkin lymphomas. New CAR T cell and engineered natural killer (NK) cell therapies show promise for future treatment options.

Keywords:
CAR T cellsCellular immunotherapyDiffuse large B cell lymphomaHigh-grade B cell lymphomaNon-Hodgkin lymphoma

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

487
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

852

Related Experiment Videos

Last Updated: Oct 6, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

487
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

852

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Non-Hodgkin lymphomas (NHL) represent a diverse group of cancers affecting lymphocytes.
  • Relapsed or refractory B cell lymphomas present significant therapeutic challenges.
  • Engineered T cell therapies have emerged as a promising treatment modality.

Purpose of the Study:

  • To review current data on engineered T cell therapies for non-Hodgkin lymphomas.
  • To explore future directions and novel approaches in this field.

Main Methods:

  • Review of current chimeric antigen receptor (CAR) T cell products approved for NHL.
  • Analysis of emerging engineered T cell products and novel CAR constructs.
  • Discussion of preclinical data and combination strategies.

Main Results:

  • Four CD19-targeted autologous CAR T cell products are currently approved.
  • These therapies have shown efficacy in relapsed/refractory B cell lymphomas.
  • Alternative engineered T cell products (e.g., dual-targeting, allogeneic CAR T, NK cells) and novel CAR constructs are under development.

Conclusions:

  • CAR T cells have significantly altered the treatment landscape for B cell lymphomas.
  • Emerging engineered cellular therapies demonstrate encouraging early data.
  • Future research holds promise for expanded and improved T cell-based treatments for NHL.